The role of short course of high-dose methylprednisolone in children with acute myeloblastic leukemia (FAB M2) presented with myeloid tumor

Pediatric Hematology and Oncology

Volumn 20, Issue 5, 2003, Pages 373-379

  Hiçsönmez, Gönül ^a   Çetin, Mualla ^a   Aslan, Deniz ^a   Özyürek, Emel ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Acute myeloblastic leukemia; Children; High dose methylprednisolone; Myeloid tumor

Indexed keywords

ANTACID AGENT; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GLUCOCORTICOID; METHYLPREDNISOLONE; MITOXANTRONE; PREDNOL L;

ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; BLAST CELL; BONE MARROW; BONE MARROW TUMOR; CASE REPORT; CELL DIFFERENTIATION; CHILD; DRUG MEGADOSE; FEMALE; HUMAN; LEUKEMIA CELL; MALE;

EID: 0037819507     PISSN: 08880018     EISSN: None     Source Type: Journal    
DOI: 10.1080/08880010390203954     Document Type: Article

References (35)

1. Woods WG, Kobrinsky N, Buckley JD, et al. Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: a Children's Cancer Group study. J Clin Oncol. 1993;11:1448-1457.
2. Jenkin RDT, AL Shabanah M, AL Nasser A, et al. Extramedullaly myeloid tumors in children: the limited value of local treatment. J Pediatr Hematol Oncol. 2000;22:34-40.
3. Bisschop MM, Revesz T, Bierings M, et al. Extramedullary infiltrates at diagnosis have no prognostic significance in children with acute myeloid leukemia. Leukemia. 2001;15:46-49.
4. Chang M, Raimondi SC, Ravindranath Y, et al. Prognostic factors in children and adolescents with acute myeloid leukemia (excluding children with Down syndrome acute promyelocytic leukemia): univariate and recursive partitioning analysis of patients treated on Pediatric Oncology Group (POG) study 8821. Leukemia. 2000;14:1201-1207.
5. Steuber CP, Civin C, Krischer J, et al. A comparison of induction and maintenance therapy for acute nonlymphoblastic leukemia in childhood: results of a Pediatric Oncology Group Study. J Clin Oncol. 1991;9:247-258.
6. Çavdar AO, Babacan E, Gözdasoglu S, et al. High-risk subgroup of myelomonocytic leukemia (AMML) with orbita-ocular granulocytic sarcoma (OOGS) in Turkish children. Acta Haematol. 1989;81:80-85.
7. Hiçsönmez G. A novel approach to treatment with high-dose steroid as a differentiation inducer in children with acute myeloblastic leukemia. Pediatr Pathol Mol Med. 2000;19:251-259.
8. Hiçsönmez G, Tuncer AM, Toksoy HB, Yenicesu I, Çetin M. Differentiation of leukemic cells induced by short-course high-dose methylprednisolone in children with different subtypes of acute myeloblastic leukemia. Leuk Lymph. 1999;33:573-580.
9. Hiçsönmez G, Tekelioglu M, Tuncer AM, Ozbek N, Cetin M, Cotter TG. Morphologic evidence of apoptosis in children with acute myeloblastic leukemia treated by high-dose methylprednisolone. Leuk Lymph. 1996;22:91-96.
10. Hiçsönmez G, Çetin M, Okur H, Erdemli E, Gürgey A. The potential effect of short-course high-dose steroid on the maturation and apoptosis of leukemic cells in a child with acute megakaryoblastic leukemia. Leuk Lymph. 2003;44:1037-1042.
11. Özbek N, Erdemli E, Hiçsönmez G, et al. Effects on methylprednisolone on human myeloid leukemic cells in vitro. Am J Hematol. 1999;60:255-259.
12. Hiçsönmez G, Özbek N, Kale G, Erdem G, Bilgic S, Hazar V. Dramatic effect of high-dose methylprednisolone on orbital granulocytic sarcoma. Pediatr Hematol Oncol. 1996;13:187-190.
13. Hiçsönmez G, Çetin M, Yenicesu I, et al. Evaluation of children with myelodysplastic syndrome: importance of extramedullary disease as a presenting symptom. Leuk Lymph. 2001;42:665-674.
14. Hiçsönmez G, Karadeniz N, Zamani VP, et al. High remission rate in acute myeloblastic leukemia in children treated with high-dose methylprednisolone. Eur J Haematol. 1992;48:215-220.
15. Hiçsönmez G, Çetin M, Yenicesu I, Tuncer AM, Aslan D, Özyürek E. Children with acute myeloblastic leukemia presenting with extramedullary infiltration: the effects of high-dose steroid treatment. submitted.
16. Hill JM, Marshall GJ, Falco DJ. Massive prednisone and prednisolone therapy in leukemia and lymphoma in the adult. J Am Geriatr Soc. 1956;4:627-640.
17. Ranney HM, Gellhorn A. The effect of massive prednisone and prednisolone therapy in leukemia and lymphoma. Am J Med. 1957;22:405-413.
18. Shanbrom E, Miller S. Critical evaluation of massive steroid therapy of acute leukemia. N Engl J Med. 1962;266:1354-1358.
19. Ryalls MR, Pinkerton CR, Meller ST, Talbot D, McElwain TJ. High-dose methylprednisolone sodium succinate as a single agent in relapsed childhood acute lymphoblastic leukaemia. Med Pediatr Oncol. 1992;20:119-123.
20. Hiçsönmez G, Özsoylu S, Onat N, Zamani VP, Gümrük F, Tuncer AM. High-dose methylprednisolone in resistant and relapsed children with acute lymphoblastic leukemia. Med Pediatr Oncol. 1994;22:68-69.
21. Shimohakamada Y, Shinohara K, Fukuda N. Remission of acute myeloblastic leukemia after severe pneumonia treated with high-dose methylprednisolone. Int J Hematol. 2001;74:173-177.
22. Sugawara T, Sato A, Shishido T, et al. Complete remission in acute myeloid leukemia after treatment with recombinant human granulocyte colony stimulating factor and high dose intravenous methylprednisolone. Br J Haematol. 1991;77:561-562.
23. + cells for the detection of minimal residual disease in adult acute myeloid leukemia. Br J Haematol. 2000;108:710-716.
24. Hiçsönmez G, Çetin M, Tunç B, Tuncer AM, Gümrük F, Yenicesu I. Dramatic resolution of pleural effusion in children with chronic myelomonocytic leukemia following short-course high-dose methylprednisolone. Leuk Lymph. 1998;29:617-623.
25. Miyoshi H, Ohki M, Nakagawa T, Honma Y. Glucocorticoids induce apoptosis in acute myeloid leukemia cell lines with a t(8;21) chromosome translocation. Leuk Res. 1997;21:45-50.
26. Song L, Cheng T. Glucocorticoid-induced growth inhibition and differentiation of a human megakaryoblastic leukemia cell line: involvement of glucocorticoid receptor. Stem Cells. 1993;11:312-318.
27. Blewitt RW, Abbott AC, Bird CC. Mode of cell death induced in human lymphoid cells by high and low doses of glucocorticoid. Br J Cancer. 1983;47:477-486.
28. Kasukabe T, Honma Y, Hozumi M, Suda T, Nishii Y. Control of proliferating potential of myeloid leukemia cells during long-term treatment with vitamin D3 analogues and other differentiation inducers in combination with antileukemic drugs: in vitro in vivo studies. Cancer Res. 1987;47:567-572.
29. Koeffler HP, Golde DW, Lippman ME. Glucocorticoid sensitivity and receptors in cells of human myelogenous leukemia lines. Cancer Res. 1980;40:563-566.
30. Lotem J, Sachs L. Control of sensitivity to induction of apoptosis in myeloid leukemic cells by differentiation and bcl-2 dependent and independent pathways. Cell Growth Differ. 1994;5:321-327.
31. Yüksel S, Saydam G, Uslu R, et al. Arsenic trioxide and methylprednisolone use different signal transduction pathways in leukemic differentiation. Leuk Res. 2002;26:391-398.
32. Kita K, Nakase K, Miwa H, et al. Phenotypical characteristics of acute myelocytic leukemia associated with the t(8;21) (q22;q22) chromosomal abnormality: frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34. Blood. 1992;80:470-477.
33. Frappaz D, Bertheas MF, Vasselon C, et al. Retro-orbital chloroma in children with t(8;21) acute myeloblastic leukemia of M2 type: two new cases and literature review. Am J Pediatr Hematol/Oncol. 1988;10:134-138.
34. Baer MR, Stewart CC, Lawrence D, et al. Expression of the neural cell adhesion molecule CD56 is associated with short remission duration and survival in acute myeloid leukemia with t(8;21) (q22;q22). Blood. 1997;90:1643-1648.
35. Raspadori D, Damiani D, Lenoci M, et al. CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia. 2001; 15:1161-1164.